Roche is developing a synthetic glycine transporter type 1 (GlyT1) inhibitor that goes by the names RG1678 or Bitopertin. If this molecule is approved as a medication it may help provide an option for individuals with schizophrenia who have already tried the natural GlyT1 inhibitor Sarcosine, or who are simply more comfortable with medication.
Understanding the role of NMDA Receptor Dysfunction in the Negative and Cognitive Symptoms of schizophrenia is not easy. This site, from Genentech and Roche, appears to be a part of the education and marketing push behind Bitopertin or RG1678, but it may contain some useful information for patients and their families. It does help explain the workings of the NMDA Receptor and the relationship between the neurotransmitters Glutamate and Glycine.
Links: Genentech / Roche – NMDA and Schizophrenia
Bitopertin or RG1678 is also mentioned in the comprehensive review of Glycine Transporter Type I Inhibitors – A Comprehensive Review from Hashimoto (PDF).